Topoisomerase I inhibitors: selectivity and cellular resistance.

Topoisomerase I (top1) inhibitors (camptothecins and other structurally diverse compounds) are effective and promising anticancer agents. Determinants of selectivity toward cancer cells and resistance are multifactorial. These factors can be separated in three groups. The first is related to alterations in drug distribution and metabolism. The second group includes both quantitative and qualitative (mutations) differences in top I. The third group includes resistance and sensitivity factors downstream from the cleavage complexes. They include DNA repair, cell cycle checkpoints and apoptosis, and are probably key to the relative selectivity of camptothecins toward cancer cells and to clinical resistance. Copyright 1999 Harcourt Publishers Ltd.

[1]  Y. Pommier,et al.  Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. , 1999, Cancer research.

[2]  J. Pouliot,et al.  Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. , 1999, Science.

[3]  J. Schellens,et al.  Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. , 1999, Cancer research.

[4]  Y. Shiloh,et al.  Targeting double-strand breaks to replicating DNA identifies a subpathway of DSB repair that is defective in ataxia-telangiectasia cells. , 1999, Biochemical and biophysical research communications.

[5]  Y. Pommier,et al.  Apoptotic response to camptothecin and 7‐hydroxystaurosporine (UCN‐01) in the 8 human breast cancer cell lines of the NCI anticancer drug screen: Multifactorial relationships with topoisomerase i, protein kinase C, Bcl‐2, p53, MDM‐2 and caspase pathways , 1999, International journal of cancer.

[6]  C. Bailly,et al.  Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents. , 1999, Cancer research.

[7]  K. Fukasawa,et al.  A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I. , 1999, Cancer research.

[8]  G. Verhaegh,et al.  Immortalization and characterization of Nijmegen Breakage syndrome fibroblasts. , 1999, Mutation research.

[9]  K. Ono,et al.  ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. , 1999, Molecular pharmacology.

[10]  Y. Pommier,et al.  Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro. , 1999, Nucleic acids research.

[11]  C. Morton,et al.  The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. , 1999, Cancer research.

[12]  K. Kohn,et al.  Replication‐mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA‐dependent protein kinase and dissociates RPA:DNA‐PK complexes , 1999, The EMBO journal.

[13]  E. Alnemri,et al.  Caspase-mediated Cleavage of DNA Topoisomerase I at Unconventional Sites during Apoptosis* , 1999, The Journal of Biological Chemistry.

[14]  J. Champoux,et al.  Structural insights into the function of type IB topoisomerases. , 1999, Current opinion in structural biology.

[15]  Y. Pommier,et al.  Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. , 1999, Journal of medicinal chemistry.

[16]  M. Poot,et al.  Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase , 1999, Human Genetics.

[17]  T. Litman,et al.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.

[18]  L. Liu,et al.  Interaction between human topoisomerase I and a novel RING finger/arginine-serine protein. , 1999, Nucleic acids research.

[19]  P. Leder,et al.  A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Y. Pommier,et al.  Induction of Topoisomerase I Cleavage Complexes by the Vinyl Chloride Adduct 1,N 6-Ethenoadenine* , 1998, The Journal of Biological Chemistry.

[21]  Y. Pommier,et al.  Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. , 1998, Biochimica et biophysica acta.

[22]  A. Larsen,et al.  Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. , 1998, Biochimica et biophysica acta.

[23]  M. Wierdl,et al.  Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. , 1998, Cancer research.

[24]  J. Holden,et al.  The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication. , 1998, Mutation research.

[25]  H. Rosing,et al.  O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan. , 1998, Anti-cancer drugs.

[26]  J N Weinstein,et al.  Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. , 1998, Journal of medicinal chemistry.

[27]  J. Verweij,et al.  Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. , 1998, British Journal of Cancer.

[28]  S. Sastry,et al.  Mechanisms for the Processing of a Frozen Topoisomerase-DNA Conjugate by Human Cell-free Extracts* , 1998, The Journal of Biological Chemistry.

[29]  Y. Pommier,et al.  Lamin B Phosphorylation by Protein Kinase Cα and Proteolysis during Apoptosis in Human Leukemia HL60 Cells* , 1998, The Journal of Biological Chemistry.

[30]  Y. Pommier,et al.  Mammalian DNA topoisomerase I activity and poisoning by camptothecin are inhibited by simian virus 40 large T antigen. , 1998, Biochemistry.

[31]  W G Hol,et al.  A model for the mechanism of human topoisomerase I. , 1998, Science.

[32]  J. Champoux,et al.  Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. , 1998, Science.

[33]  M. Ratain,et al.  Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.

[34]  G. Giaccone,et al.  CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. , 1998, British Journal of Cancer.

[35]  M. Bjornsti,et al.  Analysis of comptothecin resistance in yeast: relevance to cancer therapy. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[36]  J. Champoux.  Domains of human topoisomerase I and associated functions. , 1998, Progress in nucleic acid research and molecular biology.

[37]  P. D'Arpa,et al.  Replication-dependent and -independent camptothecin cytotoxicity of seven human colon tumor cell lines. , 1998, Oncology research.

[38]  C. Morton,et al.  Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. , 1998, Cancer research.

[39]  Y. Fujiwara,et al.  The Role of Glucuronidation in 7‐Ethyl‐10‐hydroxycamptothecin Resistance in vitro , 1997, Japanese journal of cancer research : Gann.

[40]  L. Liu,et al.  Processing of topoisomerase I cleavable complexes into DNA damage by transcription. , 1997, Nucleic acids research.

[41]  Y. Pommier,et al.  Trapping of Mammalian Topoisomerase I and Recombinations Induced by Damaged DNA Containing Nicks or Gaps , 1997, The Journal of Biological Chemistry.

[42]  F. Goldwasser,et al.  Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  P. D'Arpa,et al.  Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin* , 1997, The Journal of Biological Chemistry.

[44]  K. Kohn,et al.  Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. , 1997, Cancer research.

[45]  K. Kohn,et al.  Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  J. Robert,et al.  The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes Differential hydrolysis for the lactone and carboxylate forms , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[47]  G. Ireton,et al.  Reconstitution of human topoisomerase I by fragment complementation. , 1997, Journal of molecular biology.

[48]  A. Fojo,et al.  Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. , 1997, Cancer research.

[49]  L. Liu,et al.  Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. , 1997, Biochemical pharmacology.

[50]  C. Bailly,et al.  DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. , 1997, Biochemistry.

[51]  K. Kohn,et al.  Effects of Uracil Incorporation, DNA Mismatches, and Abasic Sites on Cleavage and Religation Activities of Mammalian Topoisomerase I* , 1997, The Journal of Biological Chemistry.

[52]  Y. Pommier,et al.  Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines , 1997, Cancer Chemotherapy and Pharmacology.

[53]  Y. Pommier,et al.  Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair. , 1996, Molecular pharmacology.

[54]  J. Wang,et al.  Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. , 1996, Molecular pharmacology.

[55]  A. Burgin,et al.  A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[56]  K. Kohn,et al.  Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. , 1996, Cancer research.

[57]  B. Stillman,et al.  Simian virus 40 large T antigen binds to topoisomerase I. , 1996, Virology.

[58]  J. Robert,et al.  Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. , 1996, Cancer research.

[59]  H. M. Geller,et al.  Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity , 1996, The Journal of cell biology.

[60]  D. Kufe,et al.  Identification of a Nucleolin Binding Site in Human Topoisomerase I (*) , 1996, The Journal of Biological Chemistry.

[61]  Y. Cheng,et al.  Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. , 1996, Cancer research.

[62]  Y. Pommier,et al.  Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells. , 1996, Oncology research.

[63]  K. Cowan,et al.  Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. , 1995, Cancer research.

[64]  K. Kohn,et al.  Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[65]  M. Sehested,et al.  Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. , 1995, British Journal of Cancer.

[66]  Y. Kodera,et al.  Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT‐11 (A new derivative of camptothecin) , 1995, Journal of surgical oncology.

[67]  K. Kohn,et al.  Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. , 1995, Biochemistry.

[68]  Y. Pommier,et al.  Eukaryotic DNA topoisomerases I. , 1995, Biochimica et biophysica acta.

[69]  Y. Pommier,et al.  Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. , 1995, Cancer research.

[70]  Y. Cheng,et al.  Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. , 1995, Molecular pharmacology.

[71]  Y. Pommier,et al.  Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. , 1995, Cancer research.

[72]  M. Ratain,et al.  Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.

[73]  B. Giovanella,et al.  Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice. , 1994, Cancer research.

[74]  Y. Pommier,et al.  Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. , 1994, Journal of the National Cancer Institute.

[75]  D. Kufe,et al.  Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. , 1994, The Journal of biological chemistry.

[76]  L. Liu,et al.  DNA topoisomerases: essential enzymes and lethal targets. , 1994, Annual review of pharmacology and toxicology.

[77]  K. Kohn,et al.  Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors , 1994 .

[78]  Y. Pommier,et al.  Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. , 1993, The Journal of biological chemistry.

[79]  S. Ellard,et al.  Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells. , 1993, Carcinogenesis.

[80]  M. Bjornsti,et al.  Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants. , 1993, The Journal of biological chemistry.

[81]  Y. Pommier,et al.  Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. , 1993, Molecular pharmacology.

[82]  D. Reinberg,et al.  DNA topoisomerase I is involved in both repression and activation of transcription , 1993, Nature.

[83]  J. Wang,et al.  Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. , 1993, Cancer research.

[84]  H. Strutt,et al.  Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand breaks in nascent DNA. , 1993, Cancer research.

[85]  S. Korsmeyer,et al.  Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. , 1993, Cancer research.

[86]  G. Riou,et al.  Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. , 1993, Biochemical pharmacology.

[87]  G. Hofmann,et al.  In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. , 1993, Oncology research.

[88]  N. Saijo,et al.  Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. , 1992, Biochemical and biophysical research communications.

[89]  I. Pastan,et al.  Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Y. Cheng,et al.  Characterization of camptothecin-resistant Chinese hamster lung cells. , 1992, Biochemical pharmacology.

[91]  L. Grochow,et al.  Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. , 1992, Cancer research.

[92]  Y. Pommier,et al.  Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. , 1992, Cancer research.

[93]  L. Liu,et al.  The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. , 1992, Cancer research.

[94]  N. Saijo,et al.  Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. , 1992, Cancer research.

[95]  T. Chung,et al.  Topoisomerase IIα and Topoisomerase IIβ Genes: Characterization and Mapping to Human Chromosomes 17 and 3, Respectively , 1992 .

[96]  R. Hertzberg,et al.  Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. , 1992, Oncology research.

[97]  K W Kohn,et al.  Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. , 1991, The Journal of biological chemistry.

[98]  P. Jeggo,et al.  Cross-sensitivity of γ-ray-sensitive hamster mutants to cross-linking agents , 1991 .

[99]  Eric Patterson,et al.  Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites , 1991, Nucleic Acids Res..

[100]  T. Tsuruo,et al.  Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. , 1990, Cancer research.

[101]  R. Hertzberg,et al.  Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. , 1990, Molecular pharmacology.

[102]  N. Saijo,et al.  Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. , 1990, Cancer research.

[103]  J. Thacker,et al.  DNA-break repair, radioresistance of DNA synthesis, and camptothecin sensitivity in the radiation-sensitive irs mutants: comparisons to ataxia-telangiectasia cells. , 1990, Mutation research.

[104]  T. Andoh,et al.  Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. , 1990, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[105]  M. Mattern,et al.  Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. , 1989, Journal of the National Cancer Institute.

[106]  V. Ling,et al.  Multidrug resistance in cancer. , 1989, Scientific American.

[107]  P. Smith,et al.  Enhanced sensitivity to camptothecin in ataxia-telangiectasia cells and its relationship with the expression of DNA topoisomerase I. , 1989, International journal of radiation biology.

[108]  S. Chatterjee,et al.  Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines. , 1989, Cancer communications.

[109]  R. Sternglanz,et al.  Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. , 1988, Molecular pharmacology.

[110]  R. Hertzberg,et al.  Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. , 1988, Cancer research.

[111]  J. Wang,et al.  DNA topoisomerase-targeting antitumor drugs can be studied in yeast. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[112]  Y. Suzuki,et al.  Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. , 1987, Proceedings of the National Academy of Sciences of the United States of America.